D-0189-2025 Class II Ongoing
FDA drug recall D-0189-2025 was initiated by Rising Pharma Holding, Inc. on Dec 30, 2024 and is designated Class II. Reason for recall: CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit. The recall status is ongoing. Affected quantity: 73,680 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 15, 2025
- Initiation Date
- Dec 30, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 73,680 bottles
Product description
Duloxetine Delayed-Release Capsules USP 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ NDC 57237-017-60
Reason for recall
CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.
Distribution pattern
Nationwide
Code information
Lot # DT2023003A, DT2023007A, DT2023008A, exp. date Jan-25
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0189-2025
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026